Designed Antimicrobial Peptides for Recurrent Vulvovaginal Candidiasis Treatment
Abstract
Recurrent vulvovaginal candidiasis (RVVC) is a widespread chronic infection that has a substantial negative impact on work and quality of life. The development of antimicrobial resistance and biofilm formation are speculated to contribute to Candida pathogenicity and treatment ineffectiveness. Designed antimicrobial peptides (dAMPs) are chemically modified from endogenous antimicrobial peptides that provide the first line of defense against pathogens.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Nov 01, 2019
- Source ID
- 10.1128/aac.02690-18
Entities
People
- Alfred Botha
- David A. Stevens
- Hasan Nazik
- Jesse M Jaynes
- Kathryn W. Woodburn
- L. Edward Clemens
- Lydia-marie Joubert
Organizations
- California Institute for Medical Research
- Congressionally Directed Medical Research Programs
- Stanford University
- Stellenbosch University
- Tuskegee University